Johnson & Johnson 将来の成長

Future 基準チェック /16

Johnson & Johnson利益と収益がそれぞれ年間2%と5.2%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に31.3% 2.5%なると予測されています。

主要情報

2.0%

収益成長率

2.51%

EPS成長率

Pharmaceuticals 収益成長	12.9%
収益成長率	5.2%
将来の株主資本利益率	31.34%
アナリストカバレッジ	Good
最終更新日	30 Dec 2025

今後の成長に関する最新情報

Recent updates

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Dec 18

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

May 21

業績と収益の成長予測

NYSE:JNJ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2028	109,153	25,780	25,378	32,079	8
12/31/2027	103,323	23,371	23,256	30,297	21
12/31/2026	98,517	23,446	22,744	28,645	24
12/31/2025	93,756	24,699	18,722	29,282	22
9/28/2025	92,149	25,119	18,679	24,204	N/A
6/29/2025	90,627	22,661	16,397	23,028	N/A
3/30/2025	89,331	21,810	18,574	24,783	N/A
12/29/2024	88,821	14,066	18,059	24,266	N/A
9/29/2024	87,696	14,767	19,025	25,146	N/A
6/30/2024	86,576	16,382	19,833	24,642	N/A
3/31/2024	85,648	17,072	18,234	23,191	N/A
12/31/2023	85,159	13,326	17,778	22,791	N/A
10/1/2023	83,703	12,421	15,737	20,278	N/A
7/2/2023	82,348	12,422	14,547	19,073	N/A
4/2/2023	77,458	10,730	16,207	20,472	N/A
1/1/2023	79,990	16,370	17,185	21,194	N/A
10/2/2022	84,855	17,879	17,739	21,576	N/A
7/3/2022	88,197	17,236	19,950	23,582	N/A
4/3/2022	94,880	19,830	19,733	23,315	N/A
1/2/2022	78,740	17,801	19,758	23,410	N/A
10/3/2021	91,446	17,880	22,461	26,021	N/A
7/4/2021	89,190	17,767	22,564	26,114	N/A
4/4/2021	84,214	15,115	20,853	24,252	N/A
1/3/2021	82,584	14,714	20,189	23,536	N/A
9/27/2020	80,856	16,986	18,307	21,591	N/A
6/28/2020	80,503	15,185	17,443	20,735	N/A
3/29/2020	82,729	17,166	19,764	23,231	N/A
12/29/2019	82,059	15,119	19,918	23,416	N/A
9/29/2019	81,706	14,151	19,706	23,262	N/A
6/30/2019	81,325	16,332	N/A	22,007	N/A
3/31/2019	81,593	14,679	N/A	22,138	N/A
12/30/2018	81,581	15,297	N/A	22,201	N/A
9/30/2018	81,382	1,542	N/A	22,062	N/A
7/1/2018	80,684	1,372	N/A	22,056	N/A
4/1/2018	78,693	1,245	N/A	21,749	N/A
12/31/2017	76,450	1,300	N/A	21,056	N/A
10/1/2017	74,361	15,827	N/A	21,604	N/A
7/2/2017	72,531	16,335	N/A	20,699	N/A
4/2/2017	72,174	16,505	N/A	19,491	N/A
1/1/2017	71,890	16,540	N/A	18,767	N/A
10/2/2016	71,595	15,941	N/A	17,199	N/A
7/3/2016	70,877	15,027	N/A	17,978	N/A
4/3/2016	70,182	15,546	N/A	18,886	N/A
1/3/2016	70,074	15,409	N/A	19,569	N/A
9/27/2015	70,517	14,715	N/A	18,849	N/A
6/28/2015	71,882	16,106	N/A	17,363	N/A
3/29/2015	73,590	15,916	N/A	17,420	N/A

アナリストによる今後の成長予測

収入対貯蓄率: JNJの予測収益成長率 (年間2% ) は貯蓄率 ( 3.3% ) を下回っています。

収益対市場: JNJの収益 ( 2% ) US市場 ( 15.9% ) よりも低い成長が予測されています。

高成長収益: JNJの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: JNJの収益 ( 5.2% ) US市場 ( 10.4% ) よりも低い成長が予測されています。

高い収益成長: JNJの収益 ( 5.2% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: JNJの自己資本利益率は、3年後には高くなると予測されています ( 31.3 %)

成長企業の発掘

企業分析と財務データの現状

データ	最終更新日（UTC時間）
企業分析	2026/01/02 11:03
終値	2026/01/02 00:00
収益	2025/09/28
年間収益	2024/12/29

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージ	データ	タイムフレーム	米国ソース例
会社財務	10年	損益計算書キャッシュ・フロー計算書貸借対照表	SECフォーム10-K SECフォーム10-Q
アナリストのコンセンサス予想	+プラス3年	予想財務アナリストの目標株価	アナリストリサーチレポート Blue Matrix
市場価格	30年	株価配当、分割、措置	ICEマーケットデータ SECフォームS-1
所有権	10年	トップ株主インサイダー取引	SECフォーム4 SECフォーム13D
マネジメント	10年	リーダーシップ・チーム取締役会	SECフォーム10-K SECフォームDEF 14A
主な進展	10年	会社からのお知らせ	SECフォーム8-K

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用^。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

このレポートの作成に使用した分析モデルの詳細は、Githubページでご覧いただけます。また、レポートの使用方法に関するガイドや、Youtubeでのチュートリアルもご用意しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Johnson & Johnson 24 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、。アナリストの投稿は一日中更新されます。53

アナリスト	機関
David Toung	Argus Research Company
Matthew Miksic	Barclays
Lee Hambright	Bernstein

Johnson & Johnson 将来の成長

Future 基準チェック /16

主要情報

今後の成長に関する最新情報

Johnson & Johnson Raises Earnings Guidance for 2025

Consensus EPS estimates increase by 11%

Recent updates

Johnson & Johnson Announces Quarterly Dividend for First Quarter 2026, Payable on First Quarter of 2026

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Halda Therapeutics OpCo, Inc.

Minnesota Jury Delivers $65.5 Million History-Making Verdict Against Johnson & Johnson

Los Angeles Jury Delivers $40 Million Verdict Against Johnson & Johnson in Talcum Powder Ovarian Cancer Trial

Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of RYBREVANT FASPRO

Johnson & Johnson to Report Q1, 2026 Results on Apr 14, 2026

Johnson & Johnson Announces U.S. Food and Drug Administration Approves AKEEGA as the First Precision Therapy for BRCA2-Mutated Metastatic Castration-sensitive Prostate Cancer with 54% Reduction in Disease Prostate Cancer with 54% reduction in Disease Prostate Cancer

Hagens Berman Sobol Shapiro LLP and Lowey Dannenberg, P.C. Announce Certification of a Class of Third Party Payors Who Purchased or Paid for Some or All of the Price of Stelara

Johnson & Johnson Announces Updated Results For CARVYKTI In Relapsed Or Refractory Multiple Myeloma

Johnson & Johnson's INLEXZO Delivers 74% Disease-Free Survival at One Year in Bcg-Unresponsive, High-Risk, Papillary-Only NMIBC

Johnson & Johnson (NYSE:JNJ) signed a definitive agreement to acquire Halda Therapeutics Opco, Inc. for $3.0 billion.

FDA Approves Darzalex Faspro for Adult Patients with High-Risk Smoldering Multiple Myeloma

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of Caplyta (Lumateperone)

Johnson & Johnson Announces Week 28 Results from Phase 2b ANTHEM-UC Study of Icotrokinra

Johnson & Johnson Announces Findings from the Phase 2 Dahlias Study

Johnson & Johnson Announces New Long-Term Results from the Phase 3 ICONIC-TOTAL Studya Evaluating icotrokinra

Insider notifies of intention to sell stock

Third quarter dividend of US$1.30 announced

TECVAYLI® plus DARZALEX FASPRO® Combination Regimen Significantly Improves Progression-Free Survival and Overall Survival Versus Standard of Care

Johnson & Johnson Declares Dividend for the Fourth Quarter of 2025, Payable on December 9, 2025

Third quarter 2025 earnings: Revenues exceed analysts expectations while EPS lags behind

Johnson & Johnson Raises Earnings Guidance for 2025

Johnson & Johnson to Showcase New Clinical and Real-World Data on Major Depressive Disorder Portfolio At 2025 ECNP Congress

New major risk - Revenue and earnings growth

Johnson & Johnson Announces TREMFYA® (Guselkumab) Is First and Only Il-23 Inhibitor to Demonstrate Sustained Clinical and Endoscopic Outcomes with A Fully Subcutaneous Regimen Through 48 Weeks in Ulcerative Colitis

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Tremfya®? (Guselkumab) for the Treatment of Pediatric Plaque Psoriasis and Active Psoriatic Arritis

Johnson & Johnson Announces U.S. Approval for Subcutaneous Indication in Adults with Ulcerative Colitis

Johnson & Johnson Announces an Investigational Immune-Based Indication Regimen with TECVAYLI®? (Te) and DARZALEX FASPRO®? (Daratumumab andhyaluronidase-fihj) Demonstrated Clinical Trial

Johnson & Johnson Announces New Data from the Phase 3 ICONIC-ADVANCE 1 and 2 Studies

Johnson & Johnson to Showcase Neuropsychiatry Innovations at the 2025 Psych Congress Annual Meeting

Johnson & Johnson Announces U.S. Food and Drug Administration Approves Inlexzo™? (Gemcitabine Intervesical System) Set to Transform How Certain Bladder Cancersare Treated

Johnson & Johnson Elects John Morikis to its Board of Directors and Audit Committee and Compensation & Benefits Committee

Johnson & Johnson Announces Data Publishes in the New England Journal of Medicine Demonstrate RYBREVANT (Amivantamab-Vmjw) Plus LAZCLUZE (Lazertinib) Is Re-Setting Survival Expectations in First-Line EGFR-Mutated Lung Cancer

Johnson & Johnson Announces New Analyses from the Phase 3 Mariposa Study Showing That First-Line Treatment with RYBrevant (Lazertinib) Plus Lazertinib

Johnson & Johnson to Report Q4, 2025 Results on Jan 21, 2026

Johnson & Johnson Unveils Results from the Varipure Substudy of Secure, a Real-World Study on Varipure™? Platform, at 2025 European Society of Cardiology (ESC) Congress

Johnson & Johnson Announces New Data from the DanGer Shock Randomized Control Trial, Published in the New England Journal of Medicine, Confirms the Long-Term Survival Benefit of the Impella CP Heart Pump

Upcoming dividend of US$1.30 per share

Executive VP & CFO notifies of intention to sell stock

Boston Jury Hits Johnson & Johnson with Record $42 Million Verdict in Asbestos Baby Powder Case

Johnson & Johnson Files with U.S. FDA to Include New Evidence in TREMFYA®? (Guselkumab) Label as the Only IL-23 Inhibitor to Demonstrate Significant Inhibitor to Demonstrate Significant Inhibitor of Joint Structural Damage in Active Psoriatic Arthritis

New minor risk - Financial position

Johnson & Johnson Showcases Latest Advancements in Alzheimer's Research At AAIC 2025

New major risk - Revenue and earnings growth

Johnson & Johnson Announces Submission of New Drug Application to the U.S. Food and Drug Administration

Insider recently sold US$3.1m worth of stock

Insider notifies of intention to sell stock

Second quarter 2025 earnings: EPS and revenues exceed analyst expectations

Johnson & Johnson Receives U.S. Fda Priority Review for Tar-200 Nda in High-Risk Non-Muscle Invasive Bladder Cancer

New major risk - Revenue and earnings growth

Johnson & Johnson Announces Quarterly Dividend for Third Quarter 2025, Payable on September 9, 2025

Johnson & Johnson Announces the Submission of A Supplemental New Drug Application to the U.S. Food and Drug Administration Based Upon Long-Term Data Evaluating the Safety and Efficacy of Caplyta (Lumateperone) for the Prevention of Relapse in Schizophrenia

Johnson & Johnson Announces New Data from an Indirect Treatment Comparison

Johnson & Johnson Hit with $8 Million Verdict in Massachusetts Mesothelioma Talc Lawsuit

Johnson & Johnson's Dual-Targeting CAR T-Cell Therapy Shows Encouraging First Results in Large B-Cell Lymphoma

Johnson & Johnson Announces New Data Showing TREMFYA® Significantly Inhibits Progression of Joint Structural Damage in Active Psoriatic Arthritis

Johnson & Johnson Appoints Daniel Pinto to the Board of Directors, Effective July 1, 2025

Johnson & Johnson Announces Data from Two Studies Highlighting DARZALEX FASPRO® (Daratumumab and Hyaluronidase-Fihj)

Johnson & Johnson Unveils First-In-Human Results for Pasritamig, Showing Early Anti-Tumor Activity in Prostate Cancer

Johnson & Johnson to Report Q3, 2025 Results on Oct 14, 2025

Johnson & Johnson's (NYSE:JNJ) Upcoming Dividend Will Be Larger Than Last Year's

Johnson & Johnson Announces U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Approves the Approval of the Benefit-Risk Profile of Single- Agent Darzalex Faspro®?

Upcoming dividend of US$1.30 per share

Jury Orders Johnson & Johnson to Pay $3 Million in Mesothelioma Death of New Orleans Woman

Johnson & Johnson Announces New Data from the Phase 3 ASTRO Study Evaluating TREMFYA (Guselkumab) Subcutaneous (SC) Induction Therapy in Adults with Moderately to Severely Active Ulcerative Colitis (UC)

Johnson & Johnson (NYSE:JNJ) Is Increasing Its Dividend To $1.30

Johnson & Johnson Announces Retirement of D. Adamczyk from the Board of Directors, May 31, 2025

Johnson & Johnson Receives FDA Approval for IMAAVY™? (Nipocalimab-Aahu)

Johnson & Johnson Announces New Data from Cohort 2 of the Pivotal Phase 2b SunRISe-1 Study Evaluating TAR-200

Johnson & Johnson Just Proved The Bears Wrong Again

Consensus EPS estimates increase by 11%

Johnson & Johnson Unveils Highly Anticipated and Potential Practice-Changing Data in Bladder Cancer Treatment At American Urological Association